Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An anaplastic ...

Intermittent dosing of TKI as means to prevent drug resistance has been previously explored in the past; however, different mechanisms of resistance to different TKIs in various malignancies need to ...

Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin lymphoma and a form of T-cell lymphoma. Lymphoma is a type of cancer that affects lymphocytes, a type of white blood cell. ALCL ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common ...

Researchers at Children's Hospital of Philadelphia (CHOP) unveiled a novel antibody-drug conjugate (ADC) that shows striking efficacy against cancers that express the anaplastic lymphoma kinase (ALK) ...

Nuvalent's stock has nearly doubled after positive phase 1 data from its second candidate, NVL-565, targeting ALK-positive NSCLC. The preliminary data showed early anti-tumor activity in heavily ...

ALCL is a rare white blood cell cancer. Anyone can develop it, but people with breast implants may have a greater chance of developing a particular subtype. With treatment, the outlook is usually ...

Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part of their reconstructive surgery after mastectomy were 16 times more likely ...

WEDNESDAY, June 25, 2025 (HealthDay News) -- For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell lymphoma ...